Perspective in progress of cardiovascular gene therapy

Area of Science:

• Molecular and cellular biology
• Cardiovascular medicine
• Gene therapy

Background:

• Effective cardiovascular drugs exist, but many diseases like peripheral arterial disease remain untreatable.
• Gene therapy is an emerging strategy for cardiovascular diseases, despite limitations.
• Early human trials in 1994 explored vascular endothelial growth factor (VEGF) for peripheral vascular disease.

Purpose of the Study:

• To review the future potential of gene therapy in treating cardiovascular diseases.
• To highlight advancements in gene therapy for conditions with no current effective treatments.
• To discuss the application of gene therapy in peripheral arterial disease, ischemic heart disease, and vascular graft complications.

Main Methods:

• Review of clinical trials involving angiogenic growth factors for peripheral arterial disease.
• Analysis of studies testing transcriptional process targeting, including decoy against E2F.
• Examination of genetically modified vein grafts for long-term potency in human patients.

Main Results:

• Clinical trials using angiogenic growth factors have shown promising results for peripheral arterial disease.
• Improvements in clinical symptoms have been reported for peripheral arterial disease and ischemic heart disease.
• Genetically modified vein grafts demonstrated long-term potency in human trials.

Conclusions:

• Gene therapy holds significant future potential for treating various cardiovascular diseases.
• Angiogenic growth factors and transcriptional targeting represent viable gene therapy strategies.
• Further research and clinical application of gene therapy could address unmet needs in cardiovascular medicine.